Enter multiple symbols separated by commas

Mylan Shares Rise on Improved Earnings Guidance

Mylan Laboratories raised its fiscal 2007 earnings forecast, citing the strong performance of its generic drugs business, pushing its shares up as much as 4%.

Mylan said it expects adjusted earnings of $1.60 to $1.63 a share, up from its previous guidance of $1.50 to $1.55 and excluding any contribution from the late March launch of amlodipine besylate, a generic version of Pfizer'sblockbuster Norvasc blood-pressure drug.

Wall Street analysts had, on average, been forecasting adjusted earnings of $1.53 per share, according to Reuters Estimates.

Last month, Mylan launched its generic version of Norvasc after a federal court ruled Pfizer's patent was invalid. Pfizer is planning to launch its own generic version of the drug, which had sales of $2.7 billion.

Mylan Chief Executive Robert Coury said the forecast excludes the Norvasc launch, pending decisions from U.S. regulators related to which company will get exclusive rights to market the drug initially. Still, he said he expects Norvasc to add additional upside to its revised guidance.

Contact U.S. News


    Get the best of CNBC in your inbox

    Please choose a subscription

    Please enter a valid email address
    To learn more about how we use your information,
    please read our Privacy Policy.

Don't Miss

  • Jessica Alba

    The actress' company got burned after consumers came out in droves, saying the company's sunscreen doesn't provide much sun protection at all.

  • David Einhorn, founder of Greenlight Capital.

    David Einhorn struggled in July, with his flagship Greenlight Capital LP fund dropping 6.1 percent, according to a source.

  • What a robotic sniper might look like.

    A global arms race of robotic killing machines is inevitable if countries pursue autonomous weaponry, experts said.

U.S. Video